ESTRO 37 Abstract book

S900

ESTRO 37

EP-1673 Can APBI reduce the logistic/social impact of breast cancer treatment in Middle Income Country? A.B.B. Borges 1 , C.B. Budib 1 , F.C. Batista 1 , M.D. De Mattos 1 , D.A. Cunha 1 , A.G. Zucca-Matthes 1 , S.A. McCloskey 2 1 Barretos Cancer Hospital, Radiotherapy, Barretos, Brazil 2 UCLA - University of California, Radiotherapy, Los Angeles, USA Purpose or Objective To evaluate distance between patient’s hometown (HT) and the Radiotherapy Center (RC) in patients treated with APBI (acelerated partial breast irradiation) and to review initial outcomes after implementing this technique. Material and Methods Patients treated with APBI in a Brazilian Cancer Center, between October 2014 and October 2016 were evaluated. All patients treated met the “Suitable” criteria for APBI per the ASTRO 2017 consensus statement. The radiotherapy regimen used was 10 x 3.85 Gy, 5 times per week, delivered using an external beam three dimensional conformal technique. The distance between HT and RC was calculated for each patient receiving APBI. Secondary endpoints evaluated included overall survival (OS), locoregional recurrence free survival (LRF) and acute toxicity. Acute toxicity was assessed using the RTOG / EORTC scale. Results We included 26 patients, with median follow-up of 12 months (range 7 – 26 months) and median age 70 years (range 55 – 85 y). The median elapsed days for radiation delivery was 14 days (range 11-20 days). At the time of this analysis there were no recurrences and there was one death unrelated to cancer or cancer treatment. The only observable toxicity was Grade 1 dermatitis which occurred in 19% of patients. There were no Grade 2 or higher toxicities. Distance between HT and RC was ≤50km in 23%, 51-100km in 19%, 101-200km in 8%, 201- 400km in 31%, and >400km in 19%. Conclusion More than 50% of patients receiving APBI in our initial experience live >200km from the radiation center. We believe this technique can serve to significantly reduce the logistic and social impact of radiation therapy, especially in low and middle income countries where treatment centers are scarce, as Brazil, by reducing the treatment days and thus time displaced from home. EP-1674 financial burden of cervical cancer in patients treated at a tertiary health facility in Nigeria M.I. Mustapha 1 , M. ALI-GOMBE 2 , A. ABDULLAHI 3 , A. ADENIPEKUN 4 , O.B. CAMPBELL 4 1 RASHEED SHEKONI TEACHING HOSPITAL, RADIATION AND CLINICAL ONCOLOGY, DUTSE, Nigeria 2 GOMBE STATE UNIVERSITY, RADIOTHERAPY, GOMBE, Nigeria 3 AHMADU BELLO UNIVERSITY, RADIATION AND CLINICAL ONCOLOGY, ZARIA, Nigeria 4 UNIVERSITY OF IBADAN, RADIOTHERAPY, IBADAN, Nigeria Purpose or Objective To estimate medical and non- medical costs (direct) incurred by cervical cancer patients during the course of treatment. Material and Methods The study was conducted between 1 st June, 2014 and 31 st March, 2015 at the Radiation Oncology Department, University College Hospital Ibadan, South West Nigeria.

All histologically diagnosed cervical cancer patients that have completed treatment and were on follow up were considered. The patients were interviewed using a set of questionnaires which addresses medical and non-medical costs. All costs were expressed in naira and converted to dollar as of January 2014 rate. The data was analysed using the Statistical Package for the Social Sciences (SPSS) version 21.0. Results Seventy-eight (78) cervical cancer patients participated in the study. The mean age of patients was 58.8 (SD=11.7) years and ranged between 35-82 years. Trading was the predominant occupation (79.5%) while civil servants (11.5%) and teachers (7.7%) constituted the rest of the study population. About 10.3% underwent surgery while most had chemotherapy (98.7%) and radiotherapy (97.4%). The commonest histology was squamous cell carcinoma (95%). Majority of the patients perceived the financial burden as a result of cervical cancer to be significant (79.5%). Also none of the patients had any health insurance that covered their treatment. Their mean annual income was $2,215.1 (SD=$3,847.8) The mean total cost incurred by patients was $2,675.9 (SD=$1,251.3) with mean medical costs accounting for $1,713.0 (SD=$889.7); surgery $1,001.6 (SD=$593.9) had the highest mean cost followed with chemotherapy $603.7 (SD=$434.2), radiotherapy $453.7 (SD=$345.4), investigations $433.0 (SD=$371.7) and consultation fee $164.8 (SD=$166.0). The mean non-medical cost was $962.9 (SD=$686.2); lodging $533.7 (SD=$358.3) had the highest mean cost followed with transportation $279.5 (SD=$198.1), feeding $256.2 (SD=$193.7) and domestic services $186.6 (SD=$204.5). Conclusion Financing cervical cancer treatment is a serious burden on patients and their caregivers in our environment as they pay out of pocket. There is need for a comprehensive health insurance program that will incorporate cancer care and help reduce the burden on our patients. EP-1675 Patients undergoing radiation therapy at risk for financial toxicity: A prospective survey study J. Palmer 1 , T. Patel 2 , H. Eldredge-Hindy 3 , S. Keith 4 , T. Patel 5 , T. Malatesta 3 , J. DiNome 3 , A. Lowther 3 , L. Ferguson 3 , S. Wagenborg 3 , J. Smyles 3 , U. Babaria 3 , R. Stabile 3 , E. Gressen 3 , S. Rudoler 3 , S. Fisher 3 1 Ohio State University, Radiation Oncology, Columbus, USA 2 Philadelphia College of Osteopathic Medicine, Intermal Medicine, Philadelphia, USA 3 Sidney Kimmel Cancer Center at Thomas Jefferson University, Department of Radiation Oncology, Philadelphia, USA 4 Thomas Jefferson University, Department of Pharmacology & Experimental Therapeutics- Division of Biostatistics, Philadelphia, USA 5 Saint Joseph’s University, Erivan K. Haub School of Business, Philadelphia, USA Purpose or Objective Little is known about the financial burden experienced by patients receiving radiation therapy. Furthermore, there are currently no financial toxicity screening tools validated for use in radiation oncology. Material and Methods Physician surveys were used to gauge provider understanding of treatment costs and their willingness to